Metrics as of 10/14/2026, 01:11 PM (Berlin time), refresh in progress.
Ocugen Stock
Ocugen, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Shankar Musunuri
- Employees
- 116
- Market cap
- $300 M
- IPO
- 03/12/2014
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to…
Ocugen stock: price history
1D
-6.5%
1W
-14.9%
1M
-13.2%
6M
-50.8%
YTD
-34.4%
1Y
-44.7%
2Y
-10.1%
5Y
-87.5%
10Y
-99.5%
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~17% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vsqueeze-release-v1.0 on 14/10/26. Not a buy or sell signal.Beta
What does this mean?
Volatility squeeze
BearishPrice swings had compressed unusually tight beforehand (volatility near a low) and are now releasing into a stronger move. Technical analysis views such tight phases as often preceding a bigger move.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Ocugen
Analyst assessment of Ocugen
PRICE TARGET LOW
US$3.50
CONSENSUS
US$5.00
MEDIAN
US$5.00
PRICE TARGET HIGH
US$6.00
0
STRONG BUY
5
BUY
1
HOLD
0
SELL
0
STRONG SELL
6
TOTAL · Buy
As of: 10/09/2026
Ocugen stock metrics
P/E
-3.51
P/B
-18.11
EV/EBITDA
-4.11
RETURN ON EQUITY
150.3%
NET MARGIN
-1,671.8%
DEBT/EQUITY
-5.31
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
93.1%
FLOAT SHARES
315,725,794
AVG. DAILY VOLUME (30D)
8,215,869
Insider transactions (SEC)
Musunuri Shankar
Musunuri Shankar
Musunuri Shankar
Musunuri Shankar
Johnson-Greene Treerita Essalima
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -6.5%
Forums (Reddit)
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Ocugen stock
What does Ocugen do?
Ocugen, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Shankar Musunuri, the company employs around 116 people.
The IPO was on 03/12/2014; the stock trades on NASDAQ under the ticker OCGN.
What do analysts say about Ocugen stock?
6 analysts rate the stock, the consensus is Buy (as of 10/09/2026).
The average price target is US$5.00, ranging from US$3.50 to US$6.00, with a median of US$5.00.
This is an external assessment, not a statement by Market Jury.
When does Ocugen report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly -17% stronger than usual.
Does Ocugen pay a dividend?
No, Ocugen currently does not pay a dividend.
Which stocks are comparable to Ocugen?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Ocugen stock analyzed?
Clicking "Analyze stock" lets five strategies assess Ocugen against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.